Back to discover
Drug

Minocycline

In clinical development
Emerging researchLate-stage developmentRising momentum
Also known as Amzeeq, Arestin, Cleeravue-M, Dynacin+15 more

Amzeeq, Arestin, Cleeravue-M, Dynacin, Emrosi, Minociclinum, Minocin, Minolira, Myrac, Solodyn, Vectrin, Ximino, Zilxi, 7-Dimethylamino-6-demethyl-6-deoxytetracycline, Minociclina, Minocyclin, (4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide, Minocycline Hydrochloride, Minocyclinum.

15
Research papers
16
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Minocycline In Neurocognitive Outcomes - Sickle Cell Disease

Clinical trial2026-05-14Results expected Q4 2027 · ClinicalTrials.gov

Stony Brook Medicine Anti-Inflammatory Trial

Clinical trial2026-04-23Results expected Q2 2031 · ClinicalTrials.gov

Effect of Oral Minocycline in Patients With Acute Stroke - a Randomized, Open Label, Prospective Trial

Clinical trial2026-03-19Results expected Q4 2028 · ClinicalTrials.gov

Guidelines of care for the management of acne vulgaris.

Research2024-01-30Journal of the American Academy of Dermatology

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Minocycline
Aliases & brands
AmzeeqArestinCleeravue-MDynacinEmrosiMinociclinumMinocinMinoliraMyracSolodynVectrinXiminoZilxi7-Dimethylamino-6-demethyl-6-deoxytetracyclineMinociclinaMinocyclin(4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamideMinocycline HydrochlorideMinocyclinum
RxNorm CUI
6980
ChEMBL ID
CHEMBL1434
ATC codes
A01AB23D10AF07J01AA08
UNII
FYY3R43WGO

Clinical trials

154 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
154
registered trials across all phases
LATEST COMPLETION 2026
16
Active studies
12
Recruiting
71
Late-stage (III+)
87
Completed
51
Discontinued
PHASE DISTRIBUTIONn = 154
Early Phase 12Phase 116Phase 1 / 222Phase 243Phase 2 / 35Phase 320Phase 428Phase N / A18

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

15 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20022025
Most influential

Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease.

The Journal of neuroscience : the official journal of the Society for Neuroscience · 2002 · 910 cites

Microglia regulate the number of neural precursor cells in the developing cerebral cortex.

The Journal of neuroscience : the official journal of the Society for Neuroscience · 2013 · 798 cites

Activated microglia contribute to the maintenance of chronic pain after spinal cord injury.

The Journal of neuroscience : the official journal of the Society for Neuroscience · 2006 · 494 cites

Guidelines of care for the management of acne vulgaris.

Journal of the American Academy of Dermatology · 2024 · 236 cites
Recent papers
Major research themes8
Acne Vulgaris1Anti-Bacterial Agents1Benzoyl Peroxide1Dermatologic Agents1Dicarboxylic Acids1Diet, High-Fat1Doxycycline1Geographic Atrophy1
Journals, researchers & institutions
Top journals
  • The Journal of neuroscience : the official journal of the Society for Neuroscience3
  • Journal of neuroinflammation2
  • Stroke2
  • BMC neurology1
  • Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie1
  • Investigative ophthalmology & visual science1
Leading researchers
  • Wong WT4
  • Chew EY3
  • Cukras CA3
  • Abraham M2
  • Arunachalam T2
  • Bailey C2
  • Bellur S2
  • Edwards DJ2
Leading institutions
free-text, unnormalised
  • National Eye Institute3
  • Bristol Eye Hospital2
  • University of California2
  • American Academy of Dermatology1
  • Beth Israel Deaconess Medical Center1
  • Brigham and Women's Hospital1

Related diseases

1 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Active research areas

Related drugs

8 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Studied across 3 of the same disease areas as Minocycline in the shared literature.

3 shared diseases1 shared paper

Studied across 3 of the same disease areas as Minocycline in the shared literature.

3 shared diseases1 shared paper

Studied across 3 of the same disease areas as Minocycline in the shared literature.

3 shared diseases1 shared paper

Studied across 2 of the same disease areas as Minocycline in the shared literature.

2 shared diseases1 shared paper

Studied across the same disease area as Minocycline in the shared literature.

1 shared disease1 shared paper

Studied across the same disease area as Minocycline in the shared literature.

1 shared disease1 shared paper

Studied across the same disease area as Minocycline in the shared literature.

1 shared disease1 shared paper

Studied across the same disease area as Minocycline in the shared literature.

1 shared disease1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials